BD announced the global commercial release of new three‑ and four‑laser configurations of its FACSDiscover A8 Cell Analyzer, adding spectral and real‑time imaging capabilities to the existing five‑laser platform.
The new models incorporate BD SpectralFX™ technology, enabling analysis of 50 or more characteristics per cell with high resolution, and BD CellView™ Image Technology, which provides high‑speed imaging to reveal spatial and morphological insights in real time. The launch also introduces near‑infrared fluorochromes RealViolet 828 and RealBlue 824, designed to work with the new analyzers and extend capabilities into the near‑infrared spectrum.
By offering lower‑cost entry points while retaining advanced spectral and imaging functionality, the new configurations broaden BD’s laboratory instrumentation lineup for academic, pharmaceutical, and biotech laboratories of all sizes. The move aligns with BD’s strategy to democratize cutting‑edge flow cytometry and imaging, positioning the company to capture a larger share of the mid‑tier market segment.
Steve Conly, BD’s worldwide president of BD Biosciences, said the expanded platform will “change how our flow cytometry core operates” and make advanced technology accessible to a broader range of research organizations. Gert Van Isterdael, head of VIB Flow Core Ghent, added that the FACSDiscover A8 “is a game changer,” opening new dimensions for research and enabling discoveries that were previously impossible.
The launch builds on the five‑laser version introduced earlier in 2025, reinforcing BD’s momentum in the flow cytometry market. The addition of spectral and imaging capabilities in a single instrument gives BD a competitive edge over rivals such as Beckman Coulter and Thermo Fisher, while the new fluorochromes support emerging research areas in immunology, cancer immunotherapy, and cell biology.
The analyzers are available for order through local sales representatives, with flexible financing options for institutions with capital constraints, allowing laboratories to adopt the technology without significant upfront investment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.